Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148017 | 1.00 | KCNH2 (0.39) | KCNH2PDGFRBPDGFRAPIK3CDPIK3CA | |
| SCHEMBL5513646 | 0.79 | KDM4E (0.36) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL5513644 | 0.79 | KDM4E (0.36) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1148040 | 0.74 | KCNH2 (0.47) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1148038 | 0.74 | KCNH2 (0.47) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1148209 | 0.73 | KCNH2 (0.39) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1148210 | 0.73 | KCNH2 (0.39) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1148213 | 0.73 | KCNH2 (0.39) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3333253 | 0.73 | NNMT (0.38) | KCNH2PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL1147916 | 0.73 | KCNH2 (0.60) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888359-B2 | Cyclohexyl or piperidinyl carboxamide antibiotic derivatives | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-02-15 | — | — | US | disclosed |
| EP-2001478-B1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105232-A1 | CYCLOHEXYL OR PIPERIDINYL CARBOXAMIDE ANTIBIOTIC DERIVATIVES | CBR3, RXFP4, ODC1 | KCNH2 897/4885PDGFRB 4055/4885PDGFRA 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.